RU2215746C2 - Гетероциклические производные глицил-бета-аланина в качестве антагонистов витронектина - Google Patents
Гетероциклические производные глицил-бета-аланина в качестве антагонистов витронектина Download PDFInfo
- Publication number
- RU2215746C2 RU2215746C2 RU2000128033/04A RU2000128033A RU2215746C2 RU 2215746 C2 RU2215746 C2 RU 2215746C2 RU 2000128033/04 A RU2000128033/04 A RU 2000128033/04A RU 2000128033 A RU2000128033 A RU 2000128033A RU 2215746 C2 RU2215746 C2 RU 2215746C2
- Authority
- RU
- Russia
- Prior art keywords
- group
- alkyl
- formula
- hydrogen atom
- compound
- Prior art date
Links
- 125000000623 heterocyclic group Chemical group 0.000 title claims abstract 7
- 239000005557 antagonist Substances 0.000 title abstract 2
- 108010036960 glycyl-beta-alanine Proteins 0.000 title abstract 2
- 102100035140 Vitronectin Human genes 0.000 title 1
- 108010031318 Vitronectin Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 20
- 125000000217 alkyl group Chemical group 0.000 claims abstract 15
- 238000000034 method Methods 0.000 claims abstract 11
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 125000001424 substituent group Chemical group 0.000 claims abstract 3
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 3
- 241000124008 Mammalia Species 0.000 claims abstract 2
- 125000003118 aryl group Chemical group 0.000 claims abstract 2
- 201000010099 disease Diseases 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 claims abstract 2
- 125000005842 heteroatom Chemical group 0.000 claims abstract 2
- 230000001404 mediated effect Effects 0.000 claims abstract 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 208000037147 Hypercalcaemia Diseases 0.000 claims 1
- 229940123038 Integrin antagonist Drugs 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 125000005140 aralkylsulfonyl group Chemical group 0.000 claims 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000148 hypercalcaemia Effects 0.000 claims 1
- 208000030915 hypercalcemia disease Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000015590 smooth muscle cell migration Effects 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000004820 halides Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- -1 hydroxy- Chemical class 0.000 abstract 1
- 230000007721 medicinal effect Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 0 *CC(c1cc(*)cc(CI)c1O)NC(CNC(C(C1)=CCC=C1NC1=NCCN1)=O)=O Chemical compound *CC(c1cc(*)cc(CI)c1O)NC(CNC(C(C1)=CCC=C1NC1=NCCN1)=O)=O 0.000 description 4
- HMJRZLWDOKQSMP-QMMMGPOBSA-N NCC(N[C@@H](CC(O)=O)c(cc(cc1Br)Cl)c1O)=O Chemical compound NCC(N[C@@H](CC(O)=O)c(cc(cc1Br)Cl)c1O)=O HMJRZLWDOKQSMP-QMMMGPOBSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8139498P | 1998-04-10 | 1998-04-10 | |
| US60/081,394 | 1998-04-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2000128033A RU2000128033A (ru) | 2003-06-20 |
| RU2215746C2 true RU2215746C2 (ru) | 2003-11-10 |
Family
ID=22163868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2000128033/04A RU2215746C2 (ru) | 1998-04-10 | 1999-04-09 | Гетероциклические производные глицил-бета-аланина в качестве антагонистов витронектина |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1070060A1 (cs) |
| JP (1) | JP2002511462A (cs) |
| KR (1) | KR20010042614A (cs) |
| CN (1) | CN1304406A (cs) |
| AR (1) | AR015759A1 (cs) |
| AU (1) | AU765294B2 (cs) |
| BR (1) | BR9910119A (cs) |
| CA (1) | CA2326665A1 (cs) |
| CZ (1) | CZ20003672A3 (cs) |
| IL (1) | IL138677A0 (cs) |
| MY (1) | MY133473A (cs) |
| NO (1) | NO20005084L (cs) |
| NZ (1) | NZ507292A (cs) |
| PL (1) | PL343406A1 (cs) |
| RU (1) | RU2215746C2 (cs) |
| TW (1) | TWI247008B (cs) |
| WO (1) | WO1999052896A1 (cs) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2845863C1 (ru) * | 2020-05-14 | 2025-08-26 | Убе Корпорейшн | Производное 1,4,5,6-тетрагидропиримидин-2-амина |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6172256B1 (en) * | 1998-03-04 | 2001-01-09 | G.D. Searle & Co. | Chiral-β-amino acid compounds and derivatives thereof |
| GB9805655D0 (en) | 1998-03-16 | 1998-05-13 | Celltech Therapeutics Ltd | Chemical compounds |
| US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
| GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
| EA200100573A1 (ru) * | 1998-12-23 | 2002-02-28 | Дж.Д.Сирл Энд Ко. | Применение ингибитора циклооксигеназы-2, ингибитора матричной металлопротеиназы, противоопухолевого лекарственного средства и факультативно облучения в качестве комбинированного способа лечения неоплазии |
| WO2000047207A1 (en) | 1999-02-09 | 2000-08-17 | Bristol-Myers Squibb Company | LACTAM INHIBITORS OF FXa AND METHOD |
| ES2231179T3 (es) | 1999-04-12 | 2005-05-16 | Aventis Pharma Limited | Compuestos de heteroarilo biciclicos sustituidos como antagonistas de la integrina. |
| GB9908355D0 (en) * | 1999-04-12 | 1999-06-09 | Rhone Poulenc Rorer Ltd | Chemical compounds |
| AU4551500A (en) * | 1999-04-28 | 2000-11-17 | Basf Aktiengesellschaft | Integrin receptor antagonists |
| US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
| US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
| DE60130910T2 (de) | 2000-04-17 | 2008-07-10 | Ucb Pharma, S.A. | Enamin-derivate als zell-adhäsionsmoleküle |
| US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
| US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
| AU2001268490A1 (en) | 2000-06-15 | 2001-12-24 | Pharmacia Corporation | Dihydrostilbene alkanoic acid derivatives useful as vitronectin antagonists |
| AU2001275724A1 (en) | 2000-08-02 | 2002-02-13 | Celltech R&D Limited | 3-substituted isoquinolin-1-yl derivatives |
| US6511973B2 (en) | 2000-08-02 | 2003-01-28 | Bristol-Myers Squibb Co. | Lactam inhibitors of FXa and method |
| DE10204789A1 (de) * | 2002-02-06 | 2003-08-14 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta6 |
| TW200307671A (en) | 2002-05-24 | 2003-12-16 | Elan Pharm Inc | Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins |
| BR0317487A (pt) * | 2002-12-20 | 2005-11-29 | Pharmacia Corp | O r-isÈmero de compostos de aminoácido beta como derivados de antagonistas de receptores de integrina |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| MX2010003849A (es) | 2007-10-18 | 2010-04-27 | Boehringer Ingelheim Int | Antagonistas de cgrp. |
| EP2065381A1 (de) | 2007-10-18 | 2009-06-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP Antagonisten |
| EP2225237A2 (de) * | 2007-11-22 | 2010-09-08 | Boehringer Ingelheim International GmbH | Organische verbindungen |
| JP5385297B2 (ja) | 2007-11-22 | 2014-01-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化合物 |
| US8716226B2 (en) | 2012-07-18 | 2014-05-06 | Saint Louis University | 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists |
| CA2878469A1 (en) | 2012-07-18 | 2014-01-23 | Saint Louis University | Beta amino acid derivatives as integrin antagonists |
| EP3148587B1 (en) | 2014-05-30 | 2021-02-24 | Pfizer Inc | Carbonitrile derivatives as selective androgen receptor modulators |
| CA3008023A1 (en) | 2015-12-30 | 2017-07-06 | Saint Louis University | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists |
| AU2017359030A1 (en) * | 2016-11-08 | 2019-06-20 | Bristol-Myers Squibb Company | Pyrrole amides as alpha v integrin inhibitors |
| KR20230011967A (ko) | 2020-05-14 | 2023-01-25 | 유비이 가부시키가이샤 | 1,4,5,6-테트라하이드로피리미딘-2-아민 유도체 |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
| JPWO2023085396A1 (cs) * | 2021-11-12 | 2023-05-19 | ||
| CN115626912B (zh) * | 2022-09-27 | 2024-03-26 | 中山大学 | 一种硫脲化合物及其制备方法与应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2089547C1 (ru) * | 1991-05-03 | 1997-09-10 | Елф Санофи | Производные n-алкиленпиперидина, способ их получения, фармацевтическая композиция на их основе, оптически чистые производные n-алкиленпиперидина |
| RU2126001C1 (ru) * | 1995-01-10 | 1999-02-10 | Самдзин Фармасьютикал Ко., Лтд | Производные пиперазина и фармацевтическая композиция на их основе |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5120859A (en) * | 1989-09-22 | 1992-06-09 | Genentech, Inc. | Chimeric amino acid analogues |
| AU702487B2 (en) * | 1995-08-30 | 1999-02-25 | G.D. Searle & Co. | Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists |
| DE19629816A1 (de) * | 1996-07-24 | 1998-01-29 | Hoechst Ag | Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
| CA2263999A1 (en) * | 1996-08-29 | 1998-03-05 | Merck & Co., Inc. | Integrin antagonists |
-
1999
- 1999-04-09 CZ CZ20003672A patent/CZ20003672A3/cs unknown
- 1999-04-09 JP JP2000543454A patent/JP2002511462A/ja active Pending
- 1999-04-09 WO PCT/US1999/004297 patent/WO1999052896A1/en not_active Ceased
- 1999-04-09 TW TW088105718A patent/TWI247008B/zh active
- 1999-04-09 BR BR9910119-0A patent/BR9910119A/pt not_active IP Right Cessation
- 1999-04-09 RU RU2000128033/04A patent/RU2215746C2/ru not_active IP Right Cessation
- 1999-04-09 NZ NZ507292A patent/NZ507292A/en unknown
- 1999-04-09 EP EP99916119A patent/EP1070060A1/en not_active Withdrawn
- 1999-04-09 CN CN99807091A patent/CN1304406A/zh active Pending
- 1999-04-09 AU AU34499/99A patent/AU765294B2/en not_active Ceased
- 1999-04-09 PL PL99343406A patent/PL343406A1/xx unknown
- 1999-04-09 AR ARP990101636A patent/AR015759A1/es unknown
- 1999-04-09 KR KR1020007011291A patent/KR20010042614A/ko not_active Ceased
- 1999-04-09 IL IL13867799A patent/IL138677A0/xx unknown
- 1999-04-09 CA CA002326665A patent/CA2326665A1/en not_active Abandoned
- 1999-04-10 MY MYPI99001398A patent/MY133473A/en unknown
-
2000
- 2000-10-09 NO NO20005084A patent/NO20005084L/no not_active Application Discontinuation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2089547C1 (ru) * | 1991-05-03 | 1997-09-10 | Елф Санофи | Производные n-алкиленпиперидина, способ их получения, фармацевтическая композиция на их основе, оптически чистые производные n-алкиленпиперидина |
| RU2126001C1 (ru) * | 1995-01-10 | 1999-02-10 | Самдзин Фармасьютикал Ко., Лтд | Производные пиперазина и фармацевтическая композиция на их основе |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2845863C1 (ru) * | 2020-05-14 | 2025-08-26 | Убе Корпорейшн | Производное 1,4,5,6-тетрагидропиримидин-2-амина |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010042614A (ko) | 2001-05-25 |
| NZ507292A (en) | 2003-12-19 |
| EP1070060A1 (en) | 2001-01-24 |
| AU3449999A (en) | 1999-11-01 |
| NO20005084D0 (no) | 2000-10-09 |
| AU765294B2 (en) | 2003-09-11 |
| MY133473A (en) | 2007-11-30 |
| CA2326665A1 (en) | 1999-10-21 |
| CN1304406A (zh) | 2001-07-18 |
| IL138677A0 (en) | 2001-10-31 |
| TWI247008B (en) | 2006-01-11 |
| AR015759A1 (es) | 2001-05-16 |
| JP2002511462A (ja) | 2002-04-16 |
| WO1999052896A1 (en) | 1999-10-21 |
| NO20005084L (no) | 2000-11-27 |
| PL343406A1 (en) | 2001-08-13 |
| CZ20003672A3 (cs) | 2001-08-15 |
| BR9910119A (pt) | 2001-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2215746C2 (ru) | Гетероциклические производные глицил-бета-аланина в качестве антагонистов витронектина | |
| RU2213089C2 (ru) | Моноциклические бензамиды производных 3- или 4-замещенного 4-(аминометил)пиперидина, способы их получения, фармацевтическая композиция, способ ее приготовления, производное карбоновой кислоты | |
| SU1184443A3 (ru) | Способ получени производных тиазола (его варианты) | |
| AP1860A (en) | Aryl fused azapolycyclic compounds. | |
| RU92004336A (ru) | Водорастворимые производные камптотецина, способ их получения, фармацевтическая композиция, способ ингибирования энзима топоизомеразы, промежуточные продукты | |
| JP6621329B2 (ja) | 新規化合物、それらの合成及びそれらの使用 | |
| RU94019334A (ru) | Ингибиторы стероид-сульфатазы | |
| RU2005113153A (ru) | Новые пиримидинамидные производные и их применение | |
| BRPI0918268A2 (pt) | inibores de cinase e métodos para uso dos mesmos | |
| RU2003115490A (ru) | Амидные производные в качестве антагонистов nmda рецептора | |
| TW202341983A (zh) | 用於降解突變kras蛋白之化合物及其應用 | |
| CN106414446A (zh) | 基于稠合嘧啶的异羟肟酸盐衍生物 | |
| DE3065304D1 (en) | Morpholine derivatives, pharmaceutical compositions containing them and processes for their preparation | |
| HUT48589A (en) | Process for production of new derivatives of substituated n-/1-hydroxi-4-piperidinil/-benzamid | |
| RU2013112871A (ru) | Соединения для лечения рака | |
| EP3350188A1 (en) | Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy | |
| JP2015533811A (ja) | Ｎ−置換ビス（フルオロアルキル）１，４−ベンゾジアゼピノン化合物 | |
| WO2021016521A1 (en) | Photo induced control of protein destruction | |
| RU96102670A (ru) | Производные 1,5-бензодиазепина | |
| CN111518076A (zh) | 具有吲哚胺-2,3-双加氧酶(ido)抑制剂的制备方法 | |
| WO2001035947A2 (en) | Treating wasting syndromes with aryloxy propanolamines | |
| RU2007128080A (ru) | Производные пирролидиния в качестве мускариновых рецепторов мз | |
| CN111741946B (zh) | 吲哚胺2,3-双加氧酶抑制剂以及它们在医学上的应用 | |
| SU1676446A3 (ru) | Способ получени производных имидазолина или пиримидина или их физиологически переносимых кислотно-аддитивных солей | |
| RU2005131735A (ru) | Химические соединения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20050410 |